Talha SARIGÖZ, Tevfik Tolga ŞAHİN, Adil BAŞKIRAN, Volkan İNCE, Sertaç USTA

The impact of tumor localization on prognosis of the patients following liver transplantation for hepatocellular carcinoma

Aim: Hepatocellular carcinoma usually occurs in the setting of liver cirrhosis and therefore, resection is not possible in majority ofthe cases. Orthotopic liver transplantation (OLS) is a gold standard treatment option in hepatocellular carcinoma. The aim of thepresent retrospective study was to evaluate the prognosis of hepatocellular carcinoma localized in left or right side of the liver inpatients who underwent OLS.Materials and Methods: 120 patients received OLS for hepatocellular carcinoma between 2007 and 2018 in the institute of livertransplantation. Tumors that were centrally located were excluded from the analysis. The remaining 104 patients were divided intotwo groups; Group 1 (right lobe, n=85 [81.7%]), Group 2 (left lobe, n=19 [18.3%]). The clinical and demographic data of the patientsalong with preoperative laboratory values such as alpha fetoprotein (AFP), gamma-glutamyl transpeptidase (GGT) and thrombocytecount were retrospectively evaluated.Results: The Median age in Group 1 and 2 were 54 (4-72) and 50.5 (37-68) years, respectively. Preoperative AFP levels in Group 1and 2 were 9.25 (1-10800) ng/ml and 13 (1.5-317) ng/ml, respectively. The Model for end stage liver disease (MELD) scores in Group1 and 2 were 12 (6-52) and 9 (6-21), respectively. None of the clinical, demographic and laboratory values along with disease-freesurvival, early mortality and recurrence were significantly different among the study groups (p>0.05).Conclusions: Although there is a big discrepancy in terms of patient’s numbers in right and left-sided tumors, our data failed toshow any survival difference among the groups. Further studies, especially in hepatocellular carcinoma beyond the Milan criteria,are needed to validate our results.

PDF

___

1. European Association For The Study Of The Liver. "EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma." J Hepatology 2012:56;908-43.
2. Kaihara S, Kiuchi T, Ueda M, et al. Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 2003;75:37-40.
3. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394.
4. Ince V, Akbulut S, Otan E, et al. Liver transplantation for hepatocellular carcinoma: Malatya Experience and Proposals for Expanded Criteria. J Gastrointest Cancer. 2020 (in press)
5. Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians 2018.
6. Choo SP, Tan WL, Goh BK, et al. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer 2016;122:3430-46.
7. Davila JA, Morgan RO, Shaib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127:1372.
8. Maucort-Boulch D, de Martel C, Franceschi S, et al. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer 2018;142:2471.
9. Rawla P, Sunkara T, Muralidharan P, et al. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn) 2018;22:141-50.
10. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
11. Yao FY, Xiao L, Bass NM, et a. Liver transplantation for Hepatocellular carcinoma: Validation of the UCSFexpanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587-96.
12. Mazzaferro V, Llovet JM, Miceli R, et al. Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
13. Gunsar F. Liver Transplantation for Hepatocellular Carcinoma Beyond the Milan Criteria. Exp Clin Transplant 2017;15:59-64.
14. Macdonald B, Sewell JL, Harper AM, et al. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. Clin Transplant 2015;29:506-12.
15. Santopaolo F, Lenci I, Milana M, et al. Liver transplantation for hepatocellular carcinoma: Where do we stand?. World J Gastroenterol 2019;25:2591- 602.
16. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001;136:25-30.
17. Cillo U, Giuliani T, Polacco M, et al. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantatin. World J Gastroenterol 2016;22:232-52.
18. Duvoux C, Roudot–Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986-94.
19. Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009;49:832-8
20. Lee SD, Kim SH, Kim SK, et al. Clinical impact of 18Ffluorodeoxyglucose positron emission tomography/computed tomography in living donor liver transplantation for advanced hepatocellular carcinoma. Transplantation 2015;99:2142-9.
21. Hong G, Suh KS, Suh SW, et al. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol 2016;64:852-9.
22. Lesurtel M, Mullhaupt B, Pestalozzi BC, et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006;6:2644.